Antivirals panel to discuss hepatitis C trials
Executive Summary
FDA's Antiviral Drugs Advisory Committee will meet Oct. 19-20 to discuss issues of clinical trial design pertaining to the development of chronic hepatitis C drugs, including the identification of appropriate control arms, study populations, endpoints and long-term follow-up. The meeting is being called "in response to the growing number of products in development for this indication." Novartis and Human Genome Sciences, Vertex Pharmaceuticals and Schering-Plough are currently developing hepatitis C therapies. The two-day meeting will be held at the Hilton in Silver Spring, Md., from 8 a.m. until 4 p.m. each day. [Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.